Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Jennifer Richer

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-Pathology
Phone303/724-3735

    Collapse Research 
    Collapse research activities and funding
    ACS-IRG-16-184-56     (Jennifer Richer)Jan 1, 2017 - Dec 1, 2019
    ACS
    Institutional Research Grant
    BC151357P1 W81XWH-16-1-0422     (Jennifer Richer and Jay Gertz)Sep 30, 2016 - Sep 30, 2019
    DOD Breast Cancer Research Program
    Molecular modeling of estrogen receptor alpha mutated breast cancer to guide new therapeutic strategies
    Role Description: Major goals: Discover the molecular and phenotypic consequences of mutations in the ligand binding domain of estrogen receptor and measure the efficacy of anti-androgens and bromodomain inhibitors in blocking the growth of ESR1 mutant breast cancer.
    Role: Co-PI
    1 R01 CA187733-01     (Jennifer Richer)Jul 15, 2015 - Jun 30, 2020
    NIH NCI
    Androgen Receptor and Intersecting Pathways Critical to Breast Cancer Subtypes
    Role Description: Major goals: Androgen receptors and intersecting pathways critical to breast cancer subtypes. Identify the molecular pathways whereby androgen receptors affect the three main subtypes of breast cancer.
    Role: PI
    W81XWH-15-1-0039     (Jennifer Richer)Apr 1, 2015 - Mar 30, 2018
    DOD Breast Cancer Research Foundation
    Targeting Tryptophan Catabolism: A Novel Method to Block Triple Negative Breast Cancer Metastasis
    Role Description: Major goal: Targeting tryptophan catabolism: a novel method to block triple negative breast cancer metastasis. Kyn binding to AhR elicits both autocrine effects as well as paracrine immune-suppressive effects.
    Role: PI
    BC120183 W81XWH-13-1-0090     (Jennifer Richer)Aug 1, 2013 - Jul 31, 2018
    DOD Breast Cancer Research Program
    Targeting Androgen Receptor in Breast Cancer: Enzalutamide as a Novel Breast Cancer Therapeutic
    Role Description: Major goal: Targeting androgen receptor in breast cancer: enzalutamide as a novel breast cancer therapeutic To determine if enzalutamide can block proliferation of ER+/AR+ breast cancer and inhibit AR+ TNBC.
    Role: PI

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Burris TP, de Vera IMS, Cote I, Flaveny CA, Wanninayake US, Chatterjee A, Walker JK, Steinauer N, Zhang J, Coons LA, Korach KS, Cain DW, Hollenberg AN, Webb P, Forrest D, Jetten AM, Edwards DP, Grimm SL, Hartig S, Lange CA, Richer JK, Sartorius CA, Tetel M, Billon C, Elgendy B, Hegazy L, Griffett K, Peinetti N, Burnstein KL, Hughes TS, Sitaula S, Stayrook KR, Culver A, Murray MH, Finck BN, Cidlowski JA. International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023. Pharmacol Rev. 2023 Nov; 75(6):1233-1318. PMID: 37586884.
      View in: PubMed
    2. Welter L, Zheng S, Setayesh SM, Morikado M, Agrawal A, Nevarez R, Naghdloo A, Pore M, Higa N, Kolatkar A, Thiele JA, Sharma P, Moore HCF, Richer JK, Elias A, Pienta KJ, Zurita AJ, Gross ME, Shishido SN, Hicks J, Velasco CR, Kuhn P. Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics. Cancers (Basel). 2023 Aug 03; 15(15). PMID: 37568766.
      View in: PubMed
    3. Elias AD, Spoelstra NS, Staley AW, Sams S, Crump LS, Vidal GA, Borges VF, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, D'Alessandro A, Zolman KL, van Bokhoven A, Zhuang Y, Gallagher RI, Wulfkuhle JD, Petricoin Iii EF, Gao D, Richer JK. Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer. NPJ Breast Cancer. 2023 May 20; 9(1):41. PMID: 37210417.
      View in: PubMed
    4. Fern?ndez NB, Sosa SM, Roberts JT, Recouvreux MS, Rocha-Viegas L, Christenson JL, Spoelstra NS, Couto FL, Raimondi AR, Richer JK, Rubinstein N. RUNX1 Is Regulated by Androgen Receptor to Promote Cancer Stem Markers and Chemotherapy Resistance in Triple Negative Breast Cancer. Cells. 2023 01 29; 12(3). PMID: 36766786.
      View in: PubMed
    5. Porman AM, Roberts JT, Duncan ED, Chrupcala ML, Levine AA, Kennedy MA, Williams MM, Richer JK, Johnson AM. A single N6-methyladenosine site regulates lncRNA HOTAIR function in breast cancer cells. PLoS Biol. 2022 11; 20(11):e3001885. PMID: 36441764.
      View in: PubMed
    6. Christenson JL, Williams MM, Richer JK. The underappreciated role of resident epithelial cell populations in metastatic progression: contributions of the lung alveolar epithelium. Am J Physiol Cell Physiol. 2022 Dec 01; 323(6):C1777-C1790. PMID: 36252127.
      View in: PubMed
    7. Crump LS, Kines KT, Richer JK, Lyons TR. Breast cancers co-opt normal mechanisms of tolerance to promote immune evasion and metastasis. Am J Physiol Cell Physiol. 2022 11 01; 323(5):C1475-C1495. PMID: 36189970.
      View in: PubMed
    8. Camp FA, Brunetti TM, Williams MM, Christenson JL, Sreekanth V, Costello JC, Hay ZLZ, Kedl RM, Richer JK, Slansky JE. Antigens Expressed by Breast Cancer Cells Undergoing EMT Stimulate Cytotoxic CD8+ T Cell Immunity. Cancers (Basel). 2022 Sep 09; 14(18). PMID: 36139558.
      View in: PubMed
    9. Williams MM, Richer JK. Revealing Molecular Mechanisms Supporting Trophoblast-Mediated Maternal Immune Tolerance. Endocrinology. 2022 08 01; 163(8). PMID: 35797586.
      View in: PubMed
    10. O'Neill KI, Kuo LW, Williams MM, Lind H, Crump LS, Hammond NG, Spoelstra NS, Caino MC, Richer JK. NPC1 Confers Metabolic Flexibility in Triple Negative Breast Cancer. Cancers (Basel). 2022 Jul 21; 14(14). PMID: 35884604.
      View in: PubMed
    11. Li Z, Spoelstra NS, Sikora MJ, Sams SB, Elias A, Richer JK, Lee AV, Oesterreich S. Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer. NPJ Breast Cancer. 2022 May 10; 8(1):62. PMID: 35538119.
      View in: PubMed
    12. Li Z, McGinn O, Wu Y, Bahreini A, Priedigkeit NM, Ding K, Onkar S, Lampenfeld C, Sartorius CA, Miller L, Rosenzweig M, Cohen O, Wagle N, Richer JK, Muller WJ, Buluwela L, Ali S, Bruno TC, Vignali DAA, Fang Y, Zhu L, Tseng GC, Gertz J, Atkinson JM, Lee AV, Oesterreich S. ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. Nat Commun. 2022 04 19; 13(1):2011. PMID: 35440136.
      View in: PubMed
    13. Li Z, Wu Y, Yates ME, Tasdemir N, Bahreini A, Chen J, Levine KM, Priedigkeit NM, Nasrazadani A, Ali S, Buluwela L, Arnesen S, Gertz J, Richer JK, Troness B, El-Ashry D, Zhang Q, Gerratana L, Zhang Y, Cristofanilli M, Montanez MA, Sundd P, Wallace CT, Watkins SC, Fumagalli C, Guerini-Rocco E, Zhu L, Tseng GC, Wagle N, Carroll JS, Jank P, Denkert C, Karsten MM, Blohmer JU, Park BH, Lucas PC, Atkinson JM, Lee AV, Oesterreich S. Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. Cancer Res. 2022 04 01; 82(7):1321-1339. PMID: 35078818.
      View in: PubMed
    14. Hanamura T, Christenson JL, O'Neill KI, Rosas E, Spoelstra NS, Williams MM, Richer JK. Secreted indicators of androgen receptor activity in breast cancer pre-clinical models. Breast Cancer Res. 2021 11 04; 23(1):102. PMID: 34736512.
      View in: PubMed
    15. Williams MM, Hafeez SA, Christenson JL, O'Neill KI, Hammond NG, Richer JK. Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways. Pharmaceuticals (Basel). 2021 Nov 02; 14(11). PMID: 34832904.
      View in: PubMed
    16. Bergholtz H, Carter JM, Cesano A, Cheang MCU, Church SE, Divakar P, Fuhrman CA, Goel S, Gong J, Guerriero JL, Hoang ML, Hwang ES, Kuasne H, Lee J, Liang Y, Mittendorf EA, Perez J, Prat A, Pusztai L, Reeves JW, Riazalhosseini Y, Richer JK, Sahin ?, Sato H, Schlam I, S?rlie T, Stover DG, Swain SM, Swarbrick A, Thompson EA, Tolaney SM, Warren SE. Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx? Digital Spatial Profiler. Cancers (Basel). 2021 Sep 04; 13(17). PMID: 34503266.
      View in: PubMed
    17. Williams MM, Christenson JL, O'Neill KI, Hafeez SA, Ihle CL, Spoelstra NS, Slansky JE, Richer JK. MicroRNA-200c restoration reveals a cytokine profile to enhance M1 macrophage polarization in breast cancer. NPJ Breast Cancer. 2021 May 27; 7(1):64. PMID: 34045467.
      View in: PubMed
    18. Christenson JL, O'Neill KI, Williams MM, Spoelstra NS, Jones KL, Trahan GD, Reese J, Van Patten ET, Elias A, Eisner JR, Richer JK. Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer. Mol Cancer Ther. 2021 06; 20(6):1062-1071. PMID: 33722849.
      View in: PubMed
    19. Rosas E, Roberts JT, O'Neill KI, Christenson JL, Williams MM, Hanamura T, Spoelstra NS, Vahrenkamp JM, Gertz J, Richer JK. A Positive Feedback Loop Between TGF? and Androgen Receptor Supports Triple-negative Breast Cancer Anoikis Resistance. Endocrinology. 2021 02 01; 162(2). PMID: 33294922.
      View in: PubMed
    20. Williams MM, Spoelstra NS, Arnesen S, O'Neill KI, Christenson JL, Reese J, Torkko KC, Goodspeed A, Rosas E, Hanamura T, Sams SB, Li Z, Oesterreich S, Riggins RB, Jacobsen BM, Elias A, Gertz J, Richer JK. Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer. Cancer Res. 2021 02 01; 81(3):732-746. PMID: 33184106.
      View in: PubMed
    21. Arnesen S, Blanchard Z, Williams MM, Berrett KC, Li Z, Oesterreich S, Richer JK, Gertz J. Estrogen Receptor Alpha Mutations in Breast Cancer Cells Cause Gene Expression Changes through Constant Activity and Secondary Effects. Cancer Res. 2021 02 01; 81(3):539-551. PMID: 33184109.
      View in: PubMed
    22. Crump LS, Wyatt GL, Rutherford TR, Richer JK, Porter WW, Lyons TR. Hormonal Regulation of Semaphorin 7a in ER+ Breast Cancer Drives Therapeutic Resistance. Cancer Res. 2021 01 01; 81(1):187-198. PMID: 33122307.
      View in: PubMed
    23. Jordan KR, Sikora MJ, Slansky JE, Minic A, Richer JK, Moroney MR, Hu J, Wolsky RJ, Watson ZL, Yamamoto TM, Costello JC, Clauset A, Behbakht K, Kumar TR, Bitler BG. The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval. Clin Cancer Res. 2020 12 01; 26(23):6362-6373. PMID: 32928797.
      View in: PubMed
    24. Sawyer BT, Qamar L, Yamamoto TM, McMellen A, Watson ZL, Richer JK, Behbakht K, Schlaepfer IR, Bitler BG. Targeting Fatty Acid Oxidation to Promote Anoikis and Inhibit Ovarian Cancer Progression. Mol Cancer Res. 2020 07; 18(7):1088-1098. PMID: 32198139.
      View in: PubMed
    25. Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Sawyer BT, Sullivan KD, Khanal S, Joshi M, Ferchaud-Roucher V, Smith H, Vanderlinden LA, Brubaker SW, Caino CM, Kim H, Espinosa JM, Richer JK, Bitler BG. Multi-Omic Approaches Identify Metabolic and Autophagy Regulators Important in Ovarian Cancer Dissemination. iScience. 2019 Sep 27; 19:474-491. PMID: 31437751.
      View in: PubMed
    26. Smith LP, Bitler BG, Richer JK, Christenson JL. Tryptophan catabolism in epithelial ovarian carcinoma. Trends Cancer Res. 2019; 14:1-9. PMID: 31736606.
      View in: PubMed
    27. MacFawn I, Wilson H, Selth LA, Leighton I, Serebriiskii I, Bleackley RC, Elzamzamy O, Farris J, Pifer PM, Richer J, Frisch SM. Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers. Mol Immunol. 2019 01; 105:137-149. PMID: 30508726.
      View in: PubMed
    28. Gordon MA, Babbs B, Cochrane DR, Bitler BG, Richer JK. The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing. Mol Carcinog. 2019 02; 58(2):196-205. PMID: 30294913.
      View in: PubMed
    29. Rogers TJ, Christenson JL, Greene LI, O'Neill KI, Williams MM, Gordon MA, Nemkov T, D'Alessandro A, Degala GD, Shin J, Tan AC, Cittelly DM, Lambert JR, Richer JK. Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression. Mol Cancer Res. 2019 01; 17(1):30-41. PMID: 30213797.
      View in: PubMed
    30. Greene LI, Bruno TC, Christenson JL, D'Alessandro A, Culp-Hill R, Torkko K, Borges VF, Slansky JE, Richer JK. A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma. Mol Cancer Res. 2019 01; 17(1):131-139. PMID: 30143553.
      View in: PubMed
    31. Christenson JL, Trepel JB, Ali HY, Lee S, Eisner JR, Baskin-Bey ES, Elias AD, Richer JK. Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer. Horm Cancer. 2018 04; 9(2):82-94. PMID: 29340907.
      View in: PubMed
    32. He L, Du Z, Xiong X, Ma H, Zhu Z, Gao H, Cao J, Li T, Li H, Yang K, Chen G, Richer JK, Gu H. Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer. Sci Rep. 2017 11 06; 7(1):14584. PMID: 29109513.
      View in: PubMed
    33. Wellberg EA, Checkley LA, Giles ED, Johnson SJ, Oljira R, Wahdan-Alaswad R, Foright RM, Dooley G, Edgerton SM, Jindal S, Johnson GC, Richer JK, Kabos P, Thor AD, Schedin P, MacLean PS, Anderson SM. The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer. Horm Cancer. 2017 12; 8(5-6):269-285. PMID: 28741260.
      View in: PubMed
    34. Barton VN, Christenson JL, Gordon MA, Greene LI, Rogers TJ, Butterfield K, Babbs B, Spoelstra NS, D'Amato NC, Elias A, Richer JK. Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer. Cancer Res. 2017 07 01; 77(13):3455-3466. PMID: 28512248.
      View in: PubMed
    35. Gordon MA, D'Amato NC, Gu H, Babbs B, Wulfkuhle J, Petricoin EF, Gallagher I, Dong T, Torkko K, Liu B, Elias A, Richer JK. Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer. Mol Cancer Ther. 2017 07; 16(7):1389-1400. PMID: 28468774.
      View in: PubMed
    36. Christenson JL, Butterfield KT, Spoelstra NS, Norris JD, Josan JS, Pollock JA, McDonnell DP, Katzenellenbogen BS, Katzenellenbogen JA, Richer JK. MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression. Horm Cancer. 2017 04; 8(2):69-77. PMID: 28194662.
      View in: PubMed
    37. Heinz RE, Rudolph MC, Ramanathan P, Spoelstra NS, Butterfield KT, Webb PG, Babbs BL, Gao H, Chen S, Gordon MA, Anderson SM, Neville MC, Gu H, Richer JK. Constitutive expression of microRNA-150 in mammary epithelium suppresses secretory activation and impairs de novo lipogenesis. Development. 2016 11 15; 143(22):4236-4248. PMID: 27729410.
      View in: PubMed
    38. D'Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK. Cooperative Dynamics of AR and ER Activity in Breast Cancer. Mol Cancer Res. 2016 11; 14(11):1054-1067. PMID: 27565181.
      View in: PubMed
    39. Barton VN, Gordon MA, Richer JK, Elias A. Anti-androgen therapy in triple-negative breast cancer. Ther Adv Med Oncol. 2016 Jul; 8(4):305-8. PMID: 27482289.
      View in: PubMed
    40. Spoelstra NS, Cittelly DM, Christenson JL, Gordon MA, Elias A, Jedlicka P, Richer JK. Dicer expression in estrogen receptor-positive versus triple-negative breast cancer: an antibody comparison. Hum Pathol. 2016 10; 56:40-51. PMID: 27260947.
      View in: PubMed
    41. D'Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra NS, Nemkov TG, D'Alessandro A, Hansen KC, Richer JK. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. Cancer Res. 2015 Nov 01; 75(21):4651-64. PMID: 26363006.
      View in: PubMed
    42. Barton VN, D'Amato NC, Gordon MA, Christenson JL, Elias A, Richer JK. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. Horm Cancer. 2015 Dec; 6(5-6):206-13. PMID: 26201402.
      View in: PubMed
    43. Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs BL, Heinz RE, Elias A, Jedlicka P, Jacobsen BM, Richer JK. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol Cancer Ther. 2015 Mar; 14(3):769-78. PMID: 25713333.
      View in: PubMed
    44. Niemeyer BF, Parrish JK, Spoelstra NS, Joyal T, Richer JK, Jedlicka P. Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes. PLoS One. 2015; 10(1):e0116895. PMID: 25603314.
      View in: PubMed
    45. Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CA. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. 2015 Jul; 34(28):3676-87. PMID: 25241899.
      View in: PubMed
    46. Wahdan-Alaswad RS, Cochrane DR, Spoelstra NS, Howe EN, Edgerton SM, Anderson SM, Thor AD, Richer JK. Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b. Horm Cancer. 2014 Dec; 5(6):374-89. PMID: 25213330.
      View in: PubMed
    47. Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, Gannon F, Kangaspeska S, Jelinek J, Issa JP, Richer JK, Elias A, McIlroy M, Young LS, Davidson NE, Schiff R, Li W, Oesterreich S. Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med. 2014 Mar 26; 6(229):229ra41. PMID: 24670685.
      View in: PubMed
    48. Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, G?mez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014 Jan 22; 16(1):R7. PMID: 24451109.
      View in: PubMed
    49. Wahdan-Alaswad R, Fan Z, Edgerton SM, Liu B, Deng XS, Arnadottir SS, Richer JK, Anderson SM, Thor AD. Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle. 2013 Dec 15; 12(24):3759-69. PMID: 24107633.
      View in: PubMed
    50. D'Amato NC, Howe EN, Richer JK. MicroRNA regulation of epithelial plasticity in cancer. Cancer Lett. 2013 Nov 28; 341(1):46-55. PMID: 23228634.
      View in: PubMed
    51. Howe EN, Cochrane DR, Cittelly DM, Richer JK. miR-200c targets a NF-?B up-regulated TrkB/NTF3 autocrine signaling loop to enhance anoikis sensitivity in triple negative breast cancer. PLoS One. 2012; 7(11):e49987. PMID: 23185507.
      View in: PubMed
    52. Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR, Spillman MA, Richer JK. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther. 2012 Dec; 11(12):2556-65. PMID: 23074172.
      View in: PubMed
    53. Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra NS, Axlund SD, Hendricks P, Jacobsen BM, Sartorius CA, Richer JK. Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. Oncogene. 2013 May 16; 32(20):2555-64. PMID: 22751119.
      View in: PubMed
    54. Howe EN, Cochrane DR, Richer JK. The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity. J Mammary Gland Biol Neoplasia. 2012 Mar; 17(1):65-77. PMID: 22350980.
      View in: PubMed
    55. Cochrane DR, Jacobsen BM, Connaghan KD, Howe EN, Bain DL, Richer JK. Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer. Mol Cell Endocrinol. 2012 May 15; 355(1):15-24. PMID: 22330642.
      View in: PubMed
    56. Cochrane DR, Spoelstra NS, Richer JK. The role of miRNAs in progesterone action. Mol Cell Endocrinol. 2012 Jun 24; 357(1-2):50-9. PMID: 21952083.
      View in: PubMed
    57. Howe EN, Cochrane DR, Richer JK. Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res. 2011 Apr 18; 13(2):R45. PMID: 21501518.
      View in: PubMed
    58. Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, Jones FE. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer. 2010 Dec 20; 9:317. PMID: 21172025.
      View in: PubMed
    59. Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS, McKinsey EL, LaPara K, Elias A, Yee D, Richer JK. MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer. Horm Cancer. 2010 Dec; 1(6):306-19. PMID: 21761362.
      View in: PubMed
    60. Cochrane DR, Cittelly DM, Richer JK. Steroid receptors and microRNAs: relationships revealed. Steroids. 2011 Jan; 76(1-2):1-10. PMID: 21093468.
      View in: PubMed
    61. Cittelly DM, Richer JK, Sartorius CA. Ovarian steroid hormones: what's hot in the stem cell pool? Breast Cancer Res. 2010; 12(4):309. PMID: 20825628.
      View in: PubMed
    62. Wright JA, Richer JK, Goodall GJ. microRNAs and EMT in mammary cells and breast cancer. J Mammary Gland Biol Neoplasia. 2010 Jun; 15(2):213-23. PMID: 20499142.
      View in: PubMed
    63. Shea C, Richer J, Tzertzinis G, Maina CV. An EcR homolog from the filarial parasite, Dirofilaria immitis requires a ligand-activated partner for transactivation. Mol Biochem Parasitol. 2010 Jun; 171(2):55-63. PMID: 20170689.
      View in: PubMed
    64. Cochrane DR, Howe EN, Spoelstra NS, Richer JK. Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. J Oncol. 2010; 2010:821717. PMID: 20049172.
      View in: PubMed
    65. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther. 2009 May; 8(5):1055-66. PMID: 19435871.
      View in: PubMed
    66. Dimitrova IK, Richer JK, Rudolph MC, Spoelstra NS, Reno EM, Medina TM, Bradford AP. Gene expression profiling of multiple leiomyomata uteri and matched normal tissue from a single patient. Fertil Steril. 2009 Jun; 91(6):2650-63. PMID: 18672237.
      View in: PubMed
    67. Singh M, Spoelstra NS, Jean A, Howe E, Torkko KC, Clark HR, Darling DS, Shroyer KR, Horwitz KB, Broaddus RR, Richer JK. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol. 2008 Jul; 21(7):912-23. PMID: 18487993.
      View in: PubMed
    68. Harvell DM, Richer JK, Singh M, Spoelstra N, Finlayson C, Borges VF, Elias AD, Horwitz KB. Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. Breast Cancer Res Treat. 2008 Dec; 112(3):489-501. PMID: 18338247.
      View in: PubMed
    69. Harvell DM, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, Trapp S, Hunter L, Dye WW, Borges VF, Elias A, Horwitz KB, Richer JK. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat. 2008 Dec; 112(3):475-88. PMID: 18327671.
      View in: PubMed
    70. McLachlan-Burgess A, McCarthy S, Griffin C, Richer J, Cutler RG, Pandey S. Differential response induced by exposure to low-dose ionizing radiation in SHSY-5Y and normal human fibroblast cells. Appl Biochem Biotechnol. 2006 Nov; 135(2):159-78. PMID: 17159239.
      View in: PubMed
    71. Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Yee D. Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. Br J Cancer. 2006 Nov 06; 95(9):1220-8. PMID: 17043687.
      View in: PubMed
    72. Balmer NN, Richer JK, Spoelstra NS, Torkko KC, Lyle PL, Singh M. Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: Correlation with clinicopathologic parameters and biomarkers. Mod Pathol. 2006 Dec; 19(12):1593-605. PMID: 16980945.
      View in: PubMed
    73. Tung L, Abdel-Hafiz H, Shen T, Harvell DM, Nitao LK, Richer JK, Sartorius CA, Takimoto GS, Horwitz KB. Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B. Mol Endocrinol. 2006 Nov; 20(11):2656-70. PMID: 16762974.
      View in: PubMed
    74. Spoelstra NS, Manning NG, Higashi Y, Darling D, Singh M, Shroyer KR, Broaddus RR, Horwitz KB, Richer JK. The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res. 2006 Apr 01; 66(7):3893-902. PMID: 16585218.
      View in: PubMed
    75. Carvajal A, Espinoza N, Kato S, Pinto M, Sadarangani A, Monso C, Aranda E, Villalon M, Richer JK, Horwitz KB, Brosens JJ, Owen GI. Progesterone pre-treatment potentiates EGF pathway signaling in the breast cancer cell line ZR-75. Breast Cancer Res Treat. 2005 Nov; 94(2):171-83. PMID: 16175315.
      View in: PubMed
    76. Harvell DM, Richer JK, Allred DC, Sartorius CA, Horwitz KB. Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. Endocrinology. 2006 Feb; 147(2):700-13. PMID: 16239301.
      View in: PubMed
    77. Bray JD, Jelinsky S, Ghatge R, Bray JA, Tunkey C, Saraf K, Jacobsen BM, Richer JK, Brown EL, Winneker RC, Horwitz KB, Lyttle CR. Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol. 2005 Dec; 97(4):328-41. PMID: 16157482.
      View in: PubMed
    78. Jacobsen BM, Schittone SA, Richer JK, Horwitz KB. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol. 2005 Mar; 19(3):574-87. PMID: 15563544.
      View in: PubMed
    79. Kato S, Pinto M, Carvajal A, Espinoza N, Monso C, Sadarangani A, Villalon M, Brosens JJ, White JO, Richer JK, Horwitz KB, Owen GI. Progesterone increases tissue factor gene expression, procoagulant activity, and invasion in the breast cancer cell line ZR-75-1. J Clin Endocrinol Metab. 2005 Feb; 90(2):1181-8. PMID: 15562024.
      View in: PubMed
    80. Wu J, Richer J, Horwitz KB, Hyder SM. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B. Cancer Res. 2004 Mar 15; 64(6):2238-44. PMID: 15026368.
      View in: PubMed
    81. Jacobsen BM, Richer JK, Sartorius CA, Horwitz KB. Expression profiling of human breast cancers and gene regulation by progesterone receptors. J Mammary Gland Biol Neoplasia. 2003 Jul; 8(3):257-68. PMID: 14973372.
      View in: PubMed
    82. Takimoto GS, Tung L, Abdel-Hafiz H, Abel MG, Sartorius CA, Richer JK, Jacobsen BM, Bain DL, Horwitz KB. Functional properties of the N-terminal region of progesterone receptors and their mechanistic relationship to structure. J Steroid Biochem Mol Biol. 2003 Jun; 85(2-5):209-19. PMID: 12943706.
      View in: PubMed
    83. Jacobsen BM, Richer JK, Schittone SA, Horwitz KB. New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. J Biol Chem. 2002 Aug 02; 277(31):27793-800. PMID: 12021276.
      View in: PubMed
    84. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem. 2002 Feb 15; 277(7):5209-18. PMID: 11717311.
      View in: PubMed
    85. Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring? J Steroid Biochem Mol Biol. 2000 Nov 30; 74(5):255-9. PMID: 11162933.
      View in: PubMed
    86. Graham JD, Bain DL, Richer JK, Jackson TA, Tung L, Horwitz KB. Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer. Steroids. 2000 Oct-Nov; 65(10-11):579-84. PMID: 11108862.
      View in: PubMed
    87. Sartorius CA, Takimoto GS, Richer JK, Tung L, Horwitz KB. Association of the Ku autoantigen/DNA-dependent protein kinase holoenzyme and poly(ADP-ribose) polymerase with the DNA binding domain of progesterone receptors. J Mol Endocrinol. 2000 Apr; 24(2):165-82. PMID: 10750018.
      View in: PubMed
    88. Nagaya T, Chen KS, Fujieda M, Ohmori S, Richer JK, Horwitz KB, Lupski JR, Seo H. Localization of the human nuclear receptor corepressor (hN-CoR) gene between the CMT1A and the SMS critical regions of chromosome 17p11.2. Genomics. 1999 Aug 01; 59(3):339-41. PMID: 10444336.
      View in: PubMed
    89. Lange CA, Richer JK, Horwitz KB. Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol. 1999 Jun; 13(6):829-36. PMID: 10379882.
      View in: PubMed
    90. Hodges YK, Richer JK, Horwitz KB, Horwitz LD. Variant estrogen and progesterone receptor messages in human vascular smooth muscle. Circulation. 1999 May 25; 99(20):2688-93. PMID: 10338464.
      View in: PubMed
    91. Richer JK, Lange CA, Manning NG, Owen G, Powell R, Horwitz KB. Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J Biol Chem. 1998 Nov 20; 273(47):31317-26. PMID: 9813040.
      View in: PubMed
    92. Lange CA, Richer JK, Shen T, Horwitz KB. Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J Biol Chem. 1998 Nov 20; 273(47):31308-16. PMID: 9813039.
      View in: PubMed
    93. Kumar NS, Richer J, Owen G, Litman E, Horwitz KB, Leslie KK. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action. Cancer Res. 1998 May 01; 58(9):1860-5. PMID: 9581825.
      View in: PubMed
    94. Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB. Progesterone regulates transcription of the p21(WAF1) cyclin- dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem. 1998 Apr 24; 273(17):10696-701. PMID: 9553133.
      View in: PubMed
    95. Richer JK, Lange CA, Wierman AM, Brooks KM, Tung L, Takimoto GS, Horwitz KB. Progesterone receptor variants found in breast cells repress transcription by wild-type receptors. Breast Cancer Res Treat. 1998 Apr; 48(3):231-41. PMID: 9598870.
      View in: PubMed
    96. Leslie KK, Kumar NS, Richer J, Owen G, Takimoto G, Horwitz KB, Lange C. Differential expression of the A and B isoforms of progesterone receptor in human endometrial cancer cells. Only progesterone receptor B is induced by estrogen and associated with strong transcriptional activation. Ann N Y Acad Sci. 1997 Sep 26; 828:17-26. PMID: 9329820.
      View in: PubMed
    97. Miller MM, James RA, Richer JK, Gordon DF, Wood WM, Horwitz KB. Progesterone regulated expression of flavin-containing monooxygenase 5 by the B-isoform of progesterone receptors: implications for tamoxifen carcinogenicity. J Clin Endocrinol Metab. 1997 Sep; 82(9):2956-61. PMID: 9284726.
      View in: PubMed
    98. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol. 1997 Jun; 11(6):693-705. PMID: 9171233.
      View in: PubMed
    99. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L. Nuclear receptor coactivators and corepressors. Mol Endocrinol. 1996 Oct; 10(10):1167-77. PMID: 9121485.
      View in: PubMed
    100. Richer JK, Hunt WG, Sakanari JA, Grieve RB. Dirofilaria immitis: effect of fluoromethyl ketone cysteine protease inhibitors on the third- to fourth-stage molt. Exp Parasitol. 1993 May; 76(3):221-31. PMID: 8500582.
      View in: PubMed
    101. Richer JK, Sakanari JA, Frank GR, Grieve RB. Dirofilaria immitis: proteases produced by third- and fourth-stage larvae. Exp Parasitol. 1992 Sep; 75(2):213-22. PMID: 1516669.
      View in: PubMed
    Richer's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (414) concept(s)
    _
    Co-Authors Expand Description
    See all (49) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)